Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2039 results

Clinical Trials / Mar 30, 2026

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Clinical Trials / Mar 30, 2026

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Clinical Trials / Mar 12, 2026

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Clinical Trials / Mar 03, 2026

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Ad hoc release / Oct 26, 2021

Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz

Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de…
Press release / Jan 25, 2017

Novartis erzielt 2016 solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust der Exklusivrechte für Gleevec in den USA wettmachen; Innovationsdynamik hält an; Aktienrückkauf angekündigt

Der Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
Press release / Jan 19, 2015

Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients

Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
Press release / Apr 25, 2017

Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
Press release / Jan 19, 2024

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2…
Press release / Mar 04, 2024

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA

The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical…